logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

EMA gives a positive opinion to Gilenya, from Novartis, for minors with multiple sclerosis

Source: actasanitaria.com

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of the drug Gilenya (fingolimod), from the pharmaceutical company Novartis, to treat children and adolescents from 10 to 17 years of age with referral forms recurrent multiple sclerosis.
If approved, said pharmaceutical company indicates that Gilenya will be the first oral therapy to modify the disease for these patients based on a randomized controlled clinical study. The population of younger patients experiences two to three times more outbreaks than adults, which often implies a more severe prognosis and an earlier disability compared to that manifested in adulthood.

In relation to this authorization of commercialization, Novartis emphasizes that it would extend the age range of Gilenya, one of the most prescribed treatments for multiple sclerosis in the whole world. It also adds that this drug has already been approved for adults with recurrent remitting forms of multiple sclerosis older than 18 years in Europe.

The executive director of this laboratory, Paul Hudson, explains that “the lives of children are greatly affected by the early onset of multiple sclerosis, from practicing sports, going to school or enjoying time with family and friends.” Therefore, it has an impact on “the urgent need to address new and effective treatments” and “with Gilenya, it is possible that we have an option that can be a substantial yesterday for young patients”.

Alleviate the impact of the disease
For his part, the director of External Affairs of the European Sclerosis Platform, Christoph Talheim, highlights that “young European patients and their families, who have been waiting for an effective therapy to modify the disease, could soon have a new option of treatment to alleviate the devastating impact of this disease. ”

The positive opinion of the CHMP was based on the Paradigms trial, “the first clinical study of its kind in multiple sclerosis expressly designed for children and adolescents aged 10 to 17 years,” notes Novartis. The European Commission will review the opinion of this Committee of the EMA and is expected to issue its final decision in three months. This measure will be applicable to the 28 member states of the European Union (EU), plus Iceland, Norway and Liechtenstein.

In Distefar we like to share this type of news that suppose an advance in diseases that affect young patients.

Related entries

13 May, 2025

Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years


Leer más
12 May, 2025

Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.


Leer más
8 May, 2025

Spain, a European success story in clinical trials of new drugs


Leer más

Recent Posts

  • Farmaindustria presents improvements to the Medicines Bill to prepare healthcare for innovation over the next 20 years
  • Fina Lladós: ‘We have before us a unique opportunity in these legislative developments to transform our healthcare and prepare it for the next 20 years’.
  • Spain, a European success story in clinical trials of new drugs
  • Joint position on the draft Medicines and Medical Devices Law
  • The global pharmaceutical industry had 12,700 drugs in development by 2024

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

MADRID DELEGATION

+34 674 575 115
28010 Madrid

Links of interest

  • Legal warning
  • Privacy policy
  • Cookies policy
  • Contact

© 2025 Distefar del Sur SL. All rights reserved. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.